Addition of tafasitamab significantly improves progression-free survival

The results of the phase 3 study (inMIND) indicate a new treatment option for relapsed or refractory follicular lymphoma: The addition of tafasitamab to lenalidomide and rituximab significantly prolonged progression-free survival.